Antigen Discovery, Inc. specializes in advanced technologies for the identification and development of novel antigens, which are critical for the creation of effective vaccines and immunotherapies. The company employs a proprietary platform that integrates high-throughput screening and bioinformatics to discover and validate antigens from a wide range of pathogens. This innovative approach allows for the rapid identification of potential vaccine candidates, significantly accelerating the development process and enhancing the precision of immune responses.

In addition to its antigen discovery capabilities, Antigen Discovery, Inc. focuses on the optimization of these antigens to improve their efficacy and safety profiles. The company utilizes cutting-edge techniques in immunology and molecular biology to refine its products, ensuring that they can elicit strong and durable immune responses. By leveraging these technologies, Antigen Discovery aims to address unmet medical needs in infectious diseases and cancer, ultimately contributing to the advancement of personalized medicine and improved health outcomes.

United States

Antigen Discovery, Inc. (formerly ImmPORT Therapeutics, Inc.) provides research services and products specializing in high throughput protein microarray technology that simplifies proteomic biomarker discovery and enables serological and immune profiling of whole proteomes.

Antigen Discovery, Inc.

Company Details